Myriad Genetics (MYGN) Tops Q3 EPS by 4c, provides guidance

Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of $0.06, $0.04 better than the analyst estimate of $0.02. Revenue for the quarter came in at $213.3 million versus the consensus estimate of $210.76 million.

GUIDANCE:

Myriad Genetics sees FY2024 EPS of $0.12-$0.14, versus the consensus of $0.10. Myriad Genetics sees FY2024 revenue of $837-843 million, versus the consensus of $841.4 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• Piper Sandler Double Downgrades Myriad Genetics (MYGN) to Underweight, 'Major Strategic Action Likely Needed'
• Putin, Xi, Trump may hold trilateral talks at APEC summit - Russia's Vesti
• Reports Of Blasts Across Iran's Southern Regions: State TV - Bloomberg